Athira Pharma Inc (nasdaq:ATHA) Share Price

Company Profile

Business description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Contact
18706 North Creek Parkway
Suite 104
BothellWA98011
USA
T: +1 425 620-8501
E: [email protected]
https://www.athira.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
26

Recommended

Shares fall despite a broadly unchanged outlook.

Nathan Zaia | 10 November 2025

Investors overly optimisitc about future prospects.

Roy Van Keulen | 10 November 2025

With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.

Dan Romanoff, CPA | 09 November 2025

Index	Last price	Change	% Change
All Ordinaries	9,083.30	26.40	0.29%
CAC 40	7,950.18	14.59	-0.18%
DAX 40	23,569.96	164.06	-0.69%
Dow JONES (US)	46,987.10	74.80	0.16%
FTSE 100	9,682.57	53.21	-0.55%
HKSE	26,241.83	244.07	-0.92%
NASDAQ	23,004.54	49.46	-0.21%
Nikkei 225	50,692.57	416.20	0.83%
NZX 50 Index	13,562.06	37.15	-0.27%
S&P 500	6,728.80	8.48	0.13%
S&P/ASX 200	8,809.30	17.50	0.20%
SSE Composite Index	3,996.53	1.02	-0.03%